United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - cyproterone acetate; ethinylestradiol - oral tablet - 2mg ; 35microgram

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

schmidt biomedtech sdn bhd - cyproterone acetate; ethinylestradiol -

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate - indicated for the treatment of signs of androgenisation in women such as severe acne (involving inflammation or nordularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. jene-35ed will also provide effective oral contraception in this patient group. if the hirsutism has only recently appeared or has lately intensified to a considerable extent, the cause (androgen-producing tumour or an adrenal enzyme defect) must be clarified by differential diagnosis.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - cyproterone acetate; ethinylestradiol - oral tablet - 2mg ; 35microgram

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

eurodrug laboratories (m) sdn. bhd. - cyproterone acetate; ethinylestradiol -

Canada - English - Health Canada

sun pharma canada inc - cyproterone acetate; ethinyl estradiol - tablet - 2mg; 0.035mg - cyproterone acetate 2mg; ethinyl estradiol 0.035mg - other miscellaneous therapeutic agents

Canada - English - Health Canada

laboratoire riva inc. - cyproterone acetate - tablet - 50mg - cyproterone acetate 50mg - other miscellaneous therapeutic agents

United Kingdom - English - myHealthbox

morningside healthcare ltd - cyproterone acetate, ethinylestradiol - film-coated tablets - 2000/35microgram - cyproterone and estrogen - treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism, in women of reproductive age. for the treatment of acne, co-cyprindiol should only be used after topical therapy or systemic antibiotic treatments have failed.

Canada - English - Health Canada

teva canada limited - cyproterone acetate; ethinyl estradiol - tablet - 2mg; 0.035mg - cyproterone acetate 2mg; ethinyl estradiol 0.035mg - other miscellaneous therapeutic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cyproterone acetate 2mg;  ; ethinylestradiol 0.035mg;   - film coated tablet - active: cyproterone acetate 2mg   ethinylestradiol 0.035mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry buff oy-3690 opadry white y-1r-7000b opaglos white 6000 povidone purified water quinoline yellow sucrose lactose monohydrate magnesium stearate microcrystalline cellulose - estelle-35 and estelle-35 ed are indicated for the treatment of androgen dependent diseases in women, such as acne (where oral antibiotics or local treatment alone has not been successful), especially pronounced forms and those which are accompanied by seborrhoea or by inflammation or formation of nodes (acne papulopustulosa, acne nodulocystica), androgenic alopecia, mild forms of hirsutism. estelle-35 and estelle-35 ed are also indicated for oral contraception in women requiring treatment for these androgen-dependent diseases; it is not recommended in women solely for contraception. estelle-35 and estelle-35 ed are also indicated for treating the symptoms of polycystic ovary syndrome.